NanoVibronix, Inc. engages in the development of noninvasive biological response-activating devices. The company is headquartered in Tyler, Texas and currently employs 15 full-time employees. The company went IPO on 2015-04-24. The firm focuses on two distinct technology platforms: Acoustic-based therapeutic technologies, including PainShield and UroShield, which utilize proprietary low-intensity surface acoustic wave (SAW) technology. These devices are intended for use in home or care settings and are designed to treat pain, reduce bacterial colonization, and disrupt biofilms. UroShield is an ultrasound-based product that is designed to prevent bacterial colonization and biofilm in urinary catheters. The ENvue Navigation Platform, which is a minimally invasive electromagnetic navigation system intended to assist clinicians in placing feeding tubes into the gastrointestinal tract. ENvue provides real-time bedside visualization of tube movement and supports informed decision-making during the placement procedure.
PT Charoen Pokphand Indonesia Tbk 주요 수익원은 Broiler이며, 최신 수익 발표에서 수익은 35,319,774,000,000입니다. 지역별로는 Indonesia이 PT Charoen Pokphand Indonesia Tbk의 주요 시장이며, 수익은 69,750,701,000,000입니다.
ENvue Medical, Inc.은 수익성이 있나요?
예, 최신 재무제표에 따르면 PT Charoen Pokphand Indonesia Tbk의 순이익은 $5,643,863입니다.
ENvue Medical, Inc.에 부채가 있나요?
예, PT Charoen Pokphand Indonesia Tbk의 부채는 11,721,593입니다.
ENvue Medical, Inc.의 발행 주식은 몇 주인가요?
PT Charoen Pokphand Indonesia Tbk의 총 발행 주식은 16,398주입니다.